Relationship between serum Asymmetrical Dimethylarginine level and urolithiasis

INTRODUCTION: In the present prospective clinical human study, we focused on researching whether or not there is a difference between metabolic syndrome (MS) positive/negative and renal stone disease (SD) positive/negative patients with regard to asymmetrical dimethylarginine (ADMA) serum levels to clarify the possible effect of endothelial cell dysfunction on renal SD.
METHODS: We included 76 patients (17 males and 59 females) who were admitted to the endocrinology and urology outpatient clinic between December 2014 and February 2018. Patients were segregated into 4 groups; group 1; MS (–) SD (-), group 2; MS (–) SD (+), group 3; MS (+) SD (-) and group 4; MS (+) SD (+). Patients’ age, sex, medical history, and anthropometric measurements were recorded. Endothelial dysfunction was assessed with serum ADMA levels.
RESULTS: The mean age was 40.1 ± 11.4 years (range: 18–59). There was a statistically significant difference between groups for mean homocysteine, uric acid and BMI values. However, there was no statistically significant difference between groups for mean CRP, age and creatinine values. The mean ADMA value was 152 ± 77 (range: 51–445). There was no statistically significant difference between groups for the mean ADMA values.
DISCUSSION AND CONCLUSION: These results showed that studies must focus on MS components separately from each other and sex distribution between patients must be homogeneous or different sexes must be examined separately. In addition, stone compositions of patients enrolled in the study must be known to arrive at more trustworthy and worthwhile results.